
    
      The single treatment group will enroll adult subjects with CF currently on stable KALYDECO®
      background therapy for a minimum of 3 months at the time of randomization. Subjects will be
      randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a
      total of 14 Days. The subjects will continue treatment with KALYDECO® throughout the study.
    
  